Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification

Crizotinib has been used to counter MET gene amplification in a number of different human malignancies. Transient response to crizotinib in MET-amplified gastric cancer has been reported, but the mechanisms of resistance are not well studied. Here, we reported a stage IV gastric cancer patient with...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Juan, Wu, Xue, Tong, Xiaoling, Wang, Xiaonan, Wei, Jia, Yang, Yang, Chang, Zhili, Mao, Yu, Shao, Yang W, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432256/
https://www.ncbi.nlm.nih.gov/pubmed/28460431
http://dx.doi.org/10.18632/oncotarget.15457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432256/
https://www.ncbi.nlm.nih.gov/pubmed/28460431
http://dx.doi.org/10.18632/oncotarget.15457

Ejemplares similares